Q-omics provides the consensus-scored TMTC1 profile across patient tissues and cancer cell-line models. TMTC1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMTC1 is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, TMTC1 RNA expression shows 19,567 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KIRP, and THYM as cancer lineages where TMTC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMTC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMTC1 survival associations across molecular data types. TMTC1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMTC1 RNA expression–survival associations across cancer types. High TMTC1 expression shows unfavorable associations in BLCA, KIRP, UCEC, ACC and HNSC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMTC1 RNA expression.
This table summarizes TMTC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TMTC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMTC1 shows lower tumor expression in KIRP, COAD, KICH, BLCA, LUAD and KIRC. The KIRP box plot shows higher TMTC1 RNA expression in normal versus tumor tissue (log2 FC = −2.151, t-test p < 0.001).
This table shows molecular features associated with TMTC1 in patient tissues and cancer cell lines. In patient samples, TMTC1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMTC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
